Global Point of Care
Take the work out of getting back to work
Social distancing, hand washing, vaccines, and mask wearing are best practices for minimizing the spread of COVID-19. Testing is another powerful tool to help us return to normalcy.
The BinaxNOW™ COVID-19 Ag Card is a fast, reliable and affordable antigen test that uses a simple nasal swab. It requires no instrumentation and gives results in just 15 minutes.
The NAVICA system is a comprehensive platform for supporting your COVID-19 testing program that works seamlessly with the BinaxNOW COVID-19 test. It features easy-to-use apps for your employees, administrators, and management, and it includes ancillary state reporting capabilities.
Take the work out of getting back to work
Social distancing, hand washing, vaccines, and mask wearing are best practices for minimizing the spread of COVID-19. Testing is another powerful tool to help us return to normalcy.
The BinaxNOW™ COVID-19 Ag Card is a fast, reliable and affordable antigen test that uses a simple nasal swab. It requires no instrumentation and gives results in just 15 minutes.
The NAVICA system is a comprehensive platform for supporting your COVID-19 testing program that works seamlessly with the BinaxNOW COVID-19 test. It features easy-to-use apps for your employees, administrators, and management, and it includes ancillary state reporting capabilities.
Individuals use this mobile app to display their NAVICA ID when getting tested, and to view and share results from select Abbott rapid COVID-19 tests.* The app is available at no charge on the App Store™ and Google Play®.
Organization use this web portal to help manage testing sites that administer Abbott rapid COVID-19 tests, manage testing populations (such as who gets tested and how often) and monitor test results.**
Testing sites use this tablet app to provide results from select Abbott rapid COVID-19 tests directly to consumers through the NAVICA Consumer App.
Organizations use this mobile app to confirm authenticity of a participant’s NAVICA™ Pass, which verifies that the individual has received a recent negative Abbott rapid COVID-19 test result.
*A negative test result will generate a digitally encrypted NAVICA Pass, similar to an airline boarding pass. NAVICA-enabled organizations will be able to verify an individual's negative COVID-19 test result by scanning the NAVICA Pass to facilitate entry into organizations.
**The NAVICA Connect Portal includes an option to report all COVID-19 test results to state authorities.
NAVICA will display a digital NAVICA Pass via a QR code, similar to an airline boarding pass, for the NAVICA user who has received a negative result from a NAVICA-enabled test site. This allows organizations to verify negative test results, enabling people to move about with greater confidence, or see a positive test result and request that the person self-quarantine to avoid infecting others.
Getting a NAVICA pass is an easy 3-step process:
The BinaxNOW COVID-19 Ag Card is a rapid lateral flow antigen test administered by a healthcare professional or a trained operator. It tests for active infection using a direct nasal swab. It provides a positive or negative result in 15 minutes with no instrument required.
Our technical services team can be reached Monday to Friday 8AM to 8PM Eastern Standard Time at (800) 257-9525. Please have the following information available so we can best assist you: phone type, phone operating version, and app version.
Watch the video to learn more about the digitally-connected rapid test and mobile app.
Google Play and the Google Play Logo are trademarks of Google LLC.
App Store and the Apple Logo are trademarks of Apple Inc.
The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
A Leader in Rapid Point-of-Care Diagnostics.
©2023 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement | Declaration for California Compliance Law.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.
